ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Status:
Terminated
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and
the safety of ABX464 in treating inflammation and preventing acute respiratory failure in
patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are
infected with SARS-CoV-2 (the MiR-AGE study).